에서 실시간으로 운영 중이에요! 자세히 알아보기

NeuBase Therapeutics, Inc. Common Stock

NBSE

시가총액 US$142만

상장 폐지됨

NBSE 종목은 2024년 5월 10일에 상장 폐지됐어요.

순위로 돌아가기

소개: NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

직원 수: 37

헬스케어 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner.

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?

NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.